• +1-646-491-9876
    • +91-20-67278686

    Search

    Degenerative Disc Disease - Pipeline Review, H1 2017

    Degenerative Disc Disease - Pipeline Review, H1 2017

    • Report Code ID: RW0001689440
    • Category Healthcare
    • No. of Pages 65
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2017, provides an overview of the Degenerative Disc Disease (Musculoskeletal Disorders) pipeline landscape.

    Degenerative disc disease is refers to degeneration of intervertebral discs of the spinal column. The main symptom of degenerative disc disease is pain, which often worsens during certain types of activity. Predisposing factors include aging and injury or trauma. Treatment includes non-steroidal anti-inflammatory drugs, muscle relaxants, pain relievers and antidepressants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Degenerative Disc Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Degenerative Disc Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 1, 1, 5, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

    Degenerative Disc Disease (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease (Musculoskeletal Disorders).
    - The pipeline guide reviews pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Degenerative Disc Disease (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Degenerative Disc Disease (Musculoskeletal Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Degenerative Disc Disease (Musculoskeletal Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Degenerative Disc Disease (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Degenerative Disc Disease - Overview
    Degenerative Disc Disease - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Degenerative Disc Disease - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Degenerative Disc Disease - Companies Involved in Therapeutics Development
    AnGes MG Inc
    Biogenomics Ltd
    Biopharm GmbH
    BioRestorative Therapies Inc
    Bone Therapeutics SA
    DiscGenics Inc
    ISTO Technologies Inc
    Osiris Therapeutics Inc
    Samumed LLC
    TissueGene Inc
    U.S. Stem Cell Inc
    Yuhan Corp
    Degenerative Disc Disease - Drug Profiles
    AdipoCell - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ALLOB - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMG-0101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMG-0103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BRTX-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dibotermin alfa biosimilar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NuQu - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OTICR-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poly N-Acetyl Glucosamine Hydrogel - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SM-04690 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Degenerative Disc Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Stem Cell Therapy for Degenerative Disc Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TG-D - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    X-0002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YH-14618 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Degenerative Disc Disease - Dormant Projects
    Degenerative Disc Disease - Product Development Milestones
    Featured News & Press Releases
    Feb 08, 2017: BioRestorative Therapies Receives FDA Clearance to Initiate Phase 2 Clinical Trial for the Treatment of Patients with Degenerative Disc Disease
    Jan 09, 2017: BioRestorative Therapies Submits IND Application to FDA to Treat Patients with Degenerative Disc Disease
    Nov 15, 2016: Samumed Presents Data for a Small Molecule Modulator of Wnt Pathway as a Potential Treatment for Degenerative Disc Disease
    Nov 01, 2016: Samumed to present data on SM-04690 at American College of Rheumatology 2016 Annual Meeting
    Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
    Sep 12, 2016: BioRestorative Therapies Announces Publication in Medical Journal of Positive Results of Long-Term Safety and Feasibility Study Using Cell Therapy to Treat Patients with Degenerative Disc Disease
    May 03, 2016: Bone Therapeutics completes recruitment of its ALLOB Phase IIA spinal fusion study
    Feb 24, 2016: Bone Therapeutics Presents ALLOB Pre-Clinical and Early Clinical Efficacy Data in Spinal Fusion at the ‘Clinical Applications of Stem Cells’ Conference
    Feb 17, 2016: Bone Therapeutics treats 12 patients without safety concerns in ALLOB Phase IIA spinal fusion trial
    Feb 09, 2016: BioRestorative Therapies Names Lead Cell-Based Lumbar Disc Therapeutic Product
    Jan 12, 2015: BioRestorative Therapies Reports Successful Meeting with FDA
    Nov 24, 2014: BioRestorative Therapies Schedules Pre-IND Meeting With FDA
    Nov 17, 2014: Bioheart Announces Expansion Of Clinical Study For Degenerative Disc Disease
    Oct 09, 2014: BioRestorative Therapies Engages Access BIO to Support Advancement of brtxDISC Program into Clinical Studies
    Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB phase II trial in spine fusion
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Degenerative Disc Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Degenerative Disc Disease - Pipeline by AnGes MG Inc, H1 2017
    Degenerative Disc Disease - Pipeline by Biogenomics Ltd, H1 2017
    Degenerative Disc Disease - Pipeline by Biopharm GmbH, H1 2017
    Degenerative Disc Disease - Pipeline by BioRestorative Therapies Inc, H1 2017
    Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H1 2017
    Degenerative Disc Disease - Pipeline by DiscGenics Inc, H1 2017
    Degenerative Disc Disease - Pipeline by ISTO Technologies Inc, H1 2017
    Degenerative Disc Disease - Pipeline by Osiris Therapeutics Inc, H1 2017
    Degenerative Disc Disease - Pipeline by Samumed LLC, H1 2017
    Degenerative Disc Disease - Pipeline by TissueGene Inc, H1 2017
    Degenerative Disc Disease - Pipeline by U.S. Stem Cell Inc, H1 2017
    Degenerative Disc Disease - Pipeline by Yuhan Corp, H1 2017
    Degenerative Disc Disease - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Degenerative Disc Disease, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AnGes MG Inc
    Biogenomics Ltd
    Biopharm GmbH
    BioRestorative Therapies Inc
    Bone Therapeutics SA
    DiscGenics Inc
    ISTO Technologies Inc
    Osiris Therapeutics Inc
    Samumed LLC
    TissueGene Inc
    U.S. Stem Cell Inc
    Yuhan Corp

    Request for Sample

    Report Url http://www.reportsweb.com//degenerative-disc-disease-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//degenerative-disc-disease-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//degenerative-disc-disease-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments